ArticleBMC pulmonary medicine2026
Clinical remission and associated factors in severe eosinophilic asthma patients treated with benralizumab: a real-world study.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to evaluate changes in clinical, functional, and inflammatory parameters in patients with severe eosinophilic asthma receiving benralizumab treatment, to determine clinical remission rates, and to explore factors associated with clinical remission.
methodsThis retrospective single-center real-world study included 33 patients with severe eosinophilic asthma treated with benralizumab at a tertiary referral center. Demographic characteristics, clinical findings, pulmonary function test results, peripheral blood eosinophil counts, and treatment responses were obtained from medical records. Baseline findings were compared with those obtained after at least 12 months of treatment. Clinical remission was defined as the absence of exacerbations, no maintenance oral corticosteroid use, well-controlled asthma, and stable or improved lung function. Factors associated with clinical remission were evaluated using multivariable Firth's penalized logistic regression.
resultsThe mean age of the 33 included patients was 54.6 ± 13.8 years, and 60.6% were female. After 12 months of treatment, clinical remission was achieved in 75.8% (25/33) of patients. The proportion of patients with well-controlled asthma increased to 90.9%, while maintenance oral corticosteroid use decreased from 48.5% to 24.2% (p = 0.008). The median annual exacerbation rate decreased from 2 to 0 (p < 0.001). Mean FEV₁ increased from 1514 mL to 2188 mL (+ 674 mL; p < 0.001), and FEV₁ (% predicted) improved from 54.9% to 76.8% (p < 0.001). Peripheral blood eosinophil counts decreased from a median of 720 cells/µL to 0 cells/µL (p < 0.001). In multivariable analysis, lower baseline exacerbation frequency (OR 0.52, 95% CI 0.27-0.91; p = 0.021) and higher baseline FEV₁ (per 100 mL increase; OR 1.27, 95% CI 1.01-1.59; p = 0.037) were associated with clinical remission.
conclusionsBenralizumab was associated with high clinical remission rates, substantial reductions in exacerbations, and significant improvements in lung function in patients with severe eosinophilic asthma. Given the limited sample size, the findings from the exploratory multivariable analysis should be interpreted with caution and require confirmation in larger prospective studies.
Indexed as
Identifiers
42919316What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.